Bio-Path Holdings shares are trading higher after the company provided an update from its ongoing Phase 1/1b clinical trial of BP1001-A in solid tumor patients and reported continued patient progress from the its ongoing Phase 2 triple combination study of prexigebersen in Acute Myeloid Leukemia.
Portfolio Pulse from Benzinga Newsdesk
Bio-Path Holdings shares rise following positive updates from their clinical trials. The company reported progress in its Phase 1/1b trial of BP1001-A for solid tumors and its Phase 2 study of prexigebersen in Acute Myeloid Leukemia.
August 21, 2024 | 11:55 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bio-Path Holdings shares increased due to positive updates from their clinical trials, indicating potential advancements in treatments for solid tumors and Acute Myeloid Leukemia.
The positive updates from Bio-Path Holdings' clinical trials suggest potential advancements in their treatment pipeline, which is likely to boost investor confidence and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100